Mild Cognitive Impairment – Epidemiology – Asia Pacific
We review the published literature, including online registries and surveys, using a systematic search with a defined date range, for the most representative epidemiological data on MCI.
We summarize the results of our review for the epidemiological estimates of prevalence that are used directly in our forecast model in the “Studies Included” table. How we used these estimates and to which countries they were applied are discussed in the text and summarized in the sources table in the relevant epidemiology population sections. We report the most relevant sources not used and the reason for not using them in the “Studies Excluded” table
Table of contents
- Mild Cognitive Impairment - Epidemiology - Asia Pacific
- Introduction
- Key Findings
- Total Prevalence of Mild Cognitive Impairment per 1,000 Among People Aged 65 or Older in 2020 and 2030
- Total Prevalence of Mild Cognitive Impairment per 1,000 Among People Aged 65 or Older in 2020 and 2030
- Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Mild Cognitive Impairment over the Next Ten Years
- Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Mild Cognitive Impairment over the Next Ten Years
- Total Prevalent Cases of Mild Cognitive Impairment by Subtype
- Total Prevalent Cases of Mild Cognitive Impairment by Subtype
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Related Market Assessment Reports
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction; in most patients, these autoantibodies target acetylcholine receptors. MG is…
